Navigation Links
Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
Date:6/25/2012

PARSIPPANY, N.J. and BETHLEHEM, Pa., June 25, 2012 /PRNewswire/ -- Today, Daiichi Sankyo, Inc. received U.S. Food and Drug Administration (FDA) approval to package product at its first United States-based packaging facility located in Bethlehem, PA. With this approval, the Company expands its global supply chain capability, helping to ensure the supply of medicine to U.S. physicians and their patients.

At this time, the 140,000 square foot facility will package some of the Company's portfolio of marketed products for cardiovascular and metabolic therapies including treatments for hypertension and heart disease, diabetes and hyperlipidemia. Looking ahead, the facility could assume additional responsibilities related to clinical trial materials and perform formulation and analytical testing for select products.

"From facility and process design to quality control and personnel flow, we incorporated leading-edge technology in the design and development of the Bethlehem facility," said Jeff Lane, Vice President, Operations, Daiichi Sankyo, Inc. "The commissioning of this facility is a major milestone for our U.S. organization and augments our ability to manufacture and distribute quality medicines."

The plant currently employs approximately 39 full-time employees and will continue to add employees until realizing its full operational goals. Responsibilities range from Line Operators and Material Handlers to Project Engineers and Quality Specialists. Daiichi Sankyo worked with a number of regional and local business leaders and organizations, including the Governor's Action Team, Lehigh Valley Economic Development Corporation, Northampton County and City of Bethlehem to make this milestone possible.

Lane added that by expanding the Company's business operations to include manufacturing in the U.S., the Company is helping to minimize risks associated with product supply, and is able to gain greater control over the life cycle of its products, from research and development through packaging and distribution.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
2. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
3. Surefire Medical Receives FDA Clearance For High-Flow Microcatheter
4. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
5. Celladon Corporation Receives Notice of Allowance from European Patent Office
6. GSK Receives FDA Approval for MenHibrix®
7. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
8. Cochlear Americas Receives FDA Approval of the Worlds Thinnest, Full Length Electrode for Cochlear Implantation
9. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
10. PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
11. ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... November 06, 2019 , ... ... today unveiled new research exploring mobile behaviors that are associated with higher weight ... Presented at ObesityWeek 2019, the new study, “Mobile Engagement Behaviors Associated With Sustained ...
(Date:11/5/2019)... ... 2019 , ... Modern Living Living with kathy ireland® is pleased ... Heidi Reaganass and Head of Channel Partnerships and Media Relations Monty Bernardi to discuss ... Goli Nutrition is a nutrition company. Their goal is to help people reach their ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... How to Build a Sponsor Risk Management Program, Friday, Nov. 15: Supplier/Vendor/Contractor ... 13-15, 2019 • Philadelphia, PA , https://www.fdanews.com/cwiche6gcp , ICH E6 ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... November 11, 2019 , ... American Family ... occupational medicine, is expanding its long-term partnership with 919 Marketing , a ... With more than 200 locations across the country, American Family Care (AFC) is ...
(Date:11/9/2019)... ... November 08, 2019 , ... Pennsylvania College ... pleased to announce that after the fourth quarter of the 2018-2019 academic year, ... 94.73% average pass rate. The College’s annual pass rate for the 2018-2019 academic ...
(Date:11/7/2019)... ... 07, 2019 , ... ALZYN, LLC today announced that The Silicon Review Magazine ... , “The Silicon Review 50 Best Companies to Watch 2019 program identifies companies which ... and winning a spot on this list indicates the company has distinguished itself from ...
(Date:11/6/2019)... ... November 06, 2019 , ... Nellson, ... bar and functional powder solutions, recently achieved FSSC 22000 Certification of GFSA standard ... pleased to share the news that we have achieved FSSC 22000 compliance at ...
(Date:11/6/2019)... ... November 06, 2019 , ... Conducting Advanced ... to Improve Inspections, An FDAnews Workshop, Nov. 13-14, 2019 • Philadelphia, PA, ... one week. , Dear FDA-Regulated Executive, , CAPA failures show up in about ...
Breaking Medicine News(10 mins):